Compare Pinterest Inc (PINS) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pinterest Inc vs Travere Therapeutics Inc. Common Stock — how do they compare? Pinterest Inc trades at $21.75 (market cap $12.67B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Pinterest Inc is far larger — about 2.6× Travere Therapeutics Inc. Common Stock's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Pinterest Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Pinterest Inc for 85 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| PINS | TVTX | |
|---|---|---|
Market Cap | $12.67B | $4.88B |
Volume | 12,391,118 | 1,668,577 |
Sector | Media | Health |
52-Week High | $35.24 | $67.52 |
52-Week Low | $15.42 | $26.79 |
Typical Hold Time | 85 Days | 0 Days |
Enterprise Value | $12.59B | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pinterest (PINS) trades at $22.36, up 4.37% today, showing strong momentum after recent earnings beats. The stock maintains a bullish technical outlook with consistent revenue growth from $2.8B in 2022 to $4.2B in 2025. Analyst consensus is strongly positive with 54% buy ratings and a $27.93 price target, representing 25% upside potential. Recent news highlights Pinterest's visual search ads launch and international monetization growth as key catalysts.
The outlook remains favorable with strong fundamentals and technical momentum, though elevated valuation ratios (P/E 65.8) and insider selling present near-term risks. Revenue growth continues at 15%+ annually while profit margins improved from negative to 9.9% in 2025. Competition in digital advertising and market volatility are key watchpoints for investors.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Pinterest Inc
Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
